Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival?

Abstract

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tu-mors. Immune surveillance is often overcome by cancer cells due to the activation of immunoreg-ulatory molecules such as programmed death protein (PD‐1) and its ligand PD‐L1, and bu-tyrophilin sub‐family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD‐1 and PD‐L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of met-astatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD‐1, PD‐L1, BTN3A1, and pan‐BTN3As levels were examined in 30 c‐KIT exon 11‐mutated mGIST patients, prior to imatinib therapy. Using specific thresholds de-rived by ROC analysis, we found that high baseline levels of sPD‐1 (>8.1 ng/mL), sPD‐L1 (>0.7 ng/mL), sBTN3A1 (>7.0 ng/mL), and pan‐BTN3As (>5.0 ng/mL) were correlated with shorter pro-gression‐free survival (PFS) and poor prognosis. Contrariwise, subjects with lower plasma concentrations exhibited a median PFS about 20 months longer than to the earlier. Finally, an additional multivariate analysis revealed that circulating levels of sPD‐L1 ≤0.7 ng/mL and pan‐sBTN3As ≤5.0 ng/mL, and the absence of KIT exon 11 deletions or delins at codons 557 and/or 558 were associated with a longer PFS in mGIST patients. Our investigation, for the first time, revealed that evaluat-ing the plasma concentration of some immune checkpoints may help prognosticate survival in mGIST patients, suggesting their potential use as prognostic biomarkers beyond the presence of KIT exon 11 Del or Delins at codons 557/558.